Schroder Investment Management Group Intra Cellular Therapies, Inc. Transaction History

Schroder Investment Management Group

$94.5 Billion
Q3 2024

A detailed history of Schroder Investment Management Group transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 924,171 shares of ITCI stock, worth $87.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

924,171

Previous 751,890 22.91%

Holding current value

$87.7 Million

Previous $51.5 Million 31.22%

% of portfolio

0.07%

Previous 0.06%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$67.99 - $80.84 $11.7 Million - $13.9 Million	172,281 Added 22.91%	924,171 $67.6 Million
Q2 2024 Aug 12, 2024	BUY	$64.76 - $79.84 $8.65 Million - $10.7 Million	133,502 Added 21.59%	751,890 $51.5 Million
Q1 2024 May 14, 2024	SELL	$64.37 - $75.65 $10.4 Million - $12.2 Million	-161,435 Reduced 20.7%	618,388 $42.8 Million
Q4 2023 Feb 13, 2024	BUY	$46.37 - $73.65 $9.71 Million - $15.4 Million	209,331 Added 36.69%	779,823 $55.9 Million
Q3 2023 Nov 14, 2023	SELL	$52.09 - $64.1 $7.78 Million - $9.58 Million	-149,419 Reduced 20.76%	570,492 $29.7 Million
Q2 2023 Aug 11, 2023	SELL	$54.67 - $66.44 $12.4 Million - $15 Million	-226,074 Reduced 23.9%	719,911 $45.6 Million
Q1 2023 May 11, 2023	BUY	$43.8 - $56.99 $3.59 Million - $4.67 Million	82,024 Added 9.49%	945,985 $51.2 Million
Q4 2022 Feb 10, 2023	SELL	$44.07 - $54.45 $598,294 - $739,213	-13,576 Reduced 1.55%	863,961 $45.7 Million
Q3 2022 Nov 10, 2022	BUY	$42.7 - $59.99 $1.58 Million - $2.22 Million	37,021 Added 4.4%	877,537 $40.8 Million
Q2 2022 Aug 11, 2022	SELL	$43.0 - $65.64 $6.17 Million - $9.41 Million	-143,397 Reduced 14.57%	840,516 $49 Million
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $7.59 Million - $12.2 Million	-195,926 Reduced 16.61%	983,913 $59.4 Million
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $1.07 Million - $1.63 Million	30,498 Added 2.65%	1,179,839 $61.8 Million
Q3 2021 Nov 12, 2021	SELL	$28.72 - $42.49 $4.48 Million - $6.62 Million	-155,849 Reduced 11.94%	1,149,341 $42.8 Million
Q2 2021 Aug 13, 2021	SELL	$29.3 - $44.5 $521,715 - $792,367	-17,806 Reduced 1.35%	1,305,190 $53.3 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $307,076 - $393,914	9,970 Added 0.76%	1,322,996 $44.9 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $7.31 Million - $10.1 Million	313,129 Added 31.32%	1,313,026 $41.8 Million
Q3 2020 Nov 13, 2020	SELL	$17.61 - $31.86 $2.11 Million - $3.81 Million	-119,645 Reduced 10.69%	999,897 $23.8 Million
Q2 2020 Aug 13, 2020	BUY	$14.35 - $26.64 $24,524 - $45,527	1,709 Added 0.15%	1,119,542 $28.7 Million
Q1 2020 May 15, 2020	BUY	$12.31 - $33.12 $4.49 Million - $12.1 Million	364,938 Added 48.47%	1,117,833 $17.3 Million
Q4 2019 Feb 11, 2020	SELL	$7.26 - $38.49 $4.91 Million - $26 Million	-675,656 Reduced 47.3%	752,895 $25.8 Million
Q3 2019 Nov 12, 2019	SELL	$7.47 - $14.03 $14,327 - $26,909	-1,918 Reduced 0.13%	1,428,551 $10.7 Million
Q2 2019 Aug 08, 2019	BUY	$10.65 - $14.29 $806,812 - $1.08 Million	75,757 Added 5.59%	1,430,469 $18.6 Million
Q1 2019 May 14, 2019	BUY	$10.9 - $14.09 $2.15 Million - $2.78 Million	197,356 Added 17.05%	1,354,712 $16.5 Million
Q4 2018 Feb 14, 2019	SELL	$10.36 - $20.96 $451,178 - $912,808	-43,550 Reduced 3.63%	1,157,356 $13.2 Million
Q3 2018 Nov 13, 2018	BUY	$17.77 - $22.9 $129,934 - $167,444	7,312 Added 0.61%	1,200,906 $26.1 Million
Q2 2018 Aug 24, 2018	BUY	$17.33 - $23.4 $20.7 Million - $27.9 Million	1,193,594 New	1,193,594 $21.2 Million

Others Institutions Holding ITCI

# of Institutions

379

Shares Held

84.1M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.96B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.

Account

Schroder Investment Management Group Intra Cellular Therapies, Inc. Transaction History